The European Medicines Agency has begun reviewing a number of new drugs for potential pan-EU marketing authorization including Novartis/BeiGene’s tislelizumab for treating both esophageal cancer and non-small cell lung cancer (NSCLC).
Tislelizumab, an anti-PD-1 monoclonal antibody, is already approved in China in seven indications
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Pink Sheet for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?